{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Incyte+Corporation", "query": { "sponsor": "Incyte Corporation", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 408, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&sponsor=Incyte+Corporation&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Incyte+Corporation&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T10:11:12.045Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06855498", "title": "Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hidradenitis Suppurativa (HS)" ], "interventions": [ { "name": "povorcitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2025-02-28", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 86, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06855498" }, { "nct_id": "NCT02018861", "title": "A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-Cell Malignancies" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Itacitinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2016-09-22", "completion_date": "2021-04-12", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Ann Arbor, Michigan • Detroit, Michigan + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02018861" }, { "nct_id": "NCT07424222", "title": "Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 16, "start_date": "2026-07-15", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07424222" }, { "nct_id": "NCT02355431", "title": "Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors and Hematologic Malignancy", "NSCLC (Non-small Cell Lung Carcinoma)" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-12", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2019-03-08", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 1, "location_summary": "Ogden, Utah", "locations": [ { "city": "Ogden", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02355431" }, { "nct_id": "NCT05635838", "title": "Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Ruxolitinib cream", "type": "DRUG" }, { "name": "Vehicle cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2022-12-07", "completion_date": "2024-03-14", "has_results": true, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05635838" }, { "nct_id": "NCT02151474", "title": "INCB047986 in Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "INCB047986", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-05", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2015-02-23", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 9, "location_summary": "Orange, California • DeBary, Florida • Palm Harbor, Florida + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "DeBary", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Frederick", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02151474" }, { "nct_id": "NCT04921969", "title": "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": 330, "start_date": "2021-07-19", "completion_date": "2024-04-08", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04921969" }, { "nct_id": "NCT04551066", "title": "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post Essential Thrombocythemia Myelofibrosis", "Post Polycythemia Vera Myelofibrosis" ], "interventions": [ { "name": "parsaclisib", "type": "DRUG" }, { "name": "ruxolitinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2021-05-24", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 36, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551066" }, { "nct_id": "NCT07015853", "title": "ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "TNBC - Triple-Negative Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Axatilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Stephen Shiao", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2026-06", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07015853" }, { "nct_id": "NCT03235544", "title": "A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2017-11-20", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2025-03-18", "last_synced_at": "2026-10-17T10:11:12.045Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Santa Rosa, California • Aurora, Colorado + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Brooksville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03235544" } ] }